October 15th 2018
Maurie Markman, MD, discusses privacy concerns associated with genetic testing.
September 29th 2018
Maurie Markman, MD, discusses the clinical benefit of early-stage trials.
September 24th 2018
Maurie Markman, MD, reflects on how technological advances have impacted translational science and clinical medicine.
August 31st 2018
In recent years there has been much discussion about the serious limitations of the conduct and interpretation of randomized trials examining the utility of antineoplastic drug therapy.
August 17th 2018
Maurie Markman, MD, says that the acceleration in regulatory agency approvals for novel antineoplastic agents and the focus of biomarker discovery proves that this is the era of precision medicine.
July 30th 2018
Maurie Markman, MD, discusses the increasing criticism of the phase III randomized trial in oncology.
July 18th 2018
Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses the latest advances in treatment for gynecological malignancies and other tumor types.
July 17th 2018
Maurie Markman, MD, defines precision medicine in oncology.
June 27th 2018
The public’s faith in science, particularly in efforts related to health, is crucial for the successful implementation of strategies designed to improve the human condition, says Maurie Markman, MD.
June 12th 2018
Maurie Markman, MD, discusses the potential to employ germline data and knowledge about the presence of specific common, uncommon, or rare variants to cancer therapy.
May 20th 2018
Maurie Markman, MD, sheds light on the debate regarding the future direction of clinical investigation.
May 15th 2018
Maurie Markman, MD, shares his thoughts on the right-to-try bill, which would allow terminally ill patients to receive investigational drugs that have been studied in phase I trials without applying through the FDA’s expanded access program.
May 10th 2018
Maurie Markman, MD, discusses the cause and impact of the opioid addiction epidemic in the United States.
April 28th 2018
It is quite difficult for those not directly involved in the complex world of academic medicine to understand fully the process of individual professional advancement and the values that organizations place on the components required for achieving and maintaining tenure.
April 3rd 2018
The impact of staggering increases in the cost of individual antineoplastic agents for patients and the overall healthcare system cannot be overstated, and there appears to be no realistic solution to the current dilemma that is acceptable to the parties involved in this ongoing debate.
March 15th 2018
One of the cardinal principles of modern medicine, as practiced in the United States, is active participation by patients—and often their families—in the process of clinical decision making.
February 28th 2018
Although median survival is a reasonable endpoint to highlight, it is only 1 of many relevant outcome factors to discuss, and, most important, this mathematical figure simply does not define the survival of any particular patient.
February 14th 2018
Decision support is only lightly touched upon in the academic oncology papers that are published almost daily suggesting a potential change in paradigms for management in a particular clinical setting.
February 7th 2018
Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses overall survival as an endpoint in ovarian cancer clinical trials.
January 31st 2018
The FDA’s recent approvals of novel anti-PARP agents as maintenance therapy for patients with previously treated advanced ovarian cancer highlight an issue that has received inadequate attention in the peer-reviewed oncology literature.